Call us: 1.405.235.2305
info@i2E.org
  • Events
  • News
  • Resources
  • Library
  • Love’s Cup
i2Ei2Ei2Ei2E
  • About
  • Entrepreneurship
    • Venture Advisory Services
    • Love’s Entrepreneur’s Cup
  • e3
  • Concept Fund
  • iMCI
  • Portfolio
  • Contact

OU Grad Dean targets drug-resistant bacteria

    Home Entrepreneur OU Grad Dean targets drug-resistant bacteria
    NextPrevious

    OU Grad Dean targets drug-resistant bacteria

    By admin | Entrepreneur, News, SeedStep Angels | Comments are Closed | 8 December, 2014 | 0
    Dr. Anne Pereira, Dean of the OUHSC Graduate School and co-founder of Biolytx Pharmaceuticals

    Dr. Anne Pereira, Dean of the OUHSC Graduate School and co-founder of Biolytx Pharmaceuticals

    By Jim Stafford

    Copyright © 2014, The Oklahoma Publishing Company

    Just a few years ago, we lived in a world that wasn’t connected by wireless networks and instantaneous communication. So you might have felt a bit isolated if you were raised in, say, Australia.

    That was definitely the perception of Anne Pereira in the early 1980s as she served a postdoctoral fellowship at the Royal Children’s Hospital in Melbourne, Australia. She had earned both her undergraduate and Ph.D. degrees in pathology at the University of Melbourne.

    “I felt I was so far away from everything that was happening in science!” Pereira said. “I decided I needed to go either to Europe or America to be where I thought science was happening. Of course, this was all pre-Internet.”

    So, she accepted a postdoctoral fellowship at Emory University in Atlanta, working in the laboratory of John Spitznagel, who chaired Emory’s Department of Microbiology from 1979 to 1993.

    It was in Spitznagel’s laboratory that Pereira, now dean of the University of Oklahoma Health Sciences Center Graduate College, discovered the secret of a protein called CAP37.

    Pereira and colleagues discovered that a peptide or small region of the CAP37 protein had the ability to kill bacteria. (Peptides are short amino acid chains that play a key role in many biological functions.) A patent was filed in 1989 for the discovery with Pereira listed as one of the inventors.

    Pereira was subsequently named an assistant professor in the Department of Pathology at the University of Oklahoma Health Sciences Center. She has served OU since 1992, rising to professor and associate dean of Research in the College of Pharmacy before being named dean of the Graduate College in August.

    Along the way, Pereira’s research into the role of peptides at her OU lab has resulted in 18 patents awarded in her name. Numerous others are in the works.

    In 2005, she founded a company called Biolytx Pharmaceuticals Corp. to take her peptide discoveries to the marketplace.

    For almost a decade, Pereira and her Biolytx team have worked to prepare a therapeutic based on the CAP37 peptide that will kill drug-resistant bacteria. Biolytx is specifically targeting serious hospital-acquired infections.

    “In combination with standard antibiotics, we may be able to extend the life of conventional antibiotics and also use them at much lower concentrations, which could result in less toxicity,” she said.

    Like most life science startups, the company has operated for almost a decade generating no revenue. However, awards and grants from i2E Inc.; the Oklahoma Center for the Advancement of Science and Technology (OCAST); the National Institutes of Health and the state’s Economic Development Generating Excellence fund have sustained it.

    Pereira and her Biolytx team have worked to synthesize the peptide in quantities large enough for use in clinical trials. Animal studies have demonstrated its effectiveness.

    The company also contracted with Oklahoma City-based ARL Laboratories to develop assays for the peptide (a laboratory examination to help learn more about its physiology) and also to assess its stability in storage.

    “We’ve really achieved some major milestones,” Pereira said. “We are actually getting very close to an investigational new drug filing. I estimate it may happen in 12 to 18 months.”

    Despite greater support for biotechnology on both the east and west coasts, Pereira is determined to build Biolytx as an Oklahoma success story.

    “Oklahoma has invested in me; the university has invested in me; and OCAST has invested in me,” she said. “I feel they have supported me to such a level that our successes in the laboratory and as a company are Oklahoma-generated and a tribute to what has been and continues to be accomplished in biotechnology here.”

    Jim Stafford writes about the state’s life sciences industry on behalf of the Oklahoma Bioscience Association.

    Read the story at newsok.com

    Anne Pereira, Biolytx Pharmaceuticals

    NextPrevious
    i2E-300dpi-Trans-Light
    • Events
    • News
    • Resources
    • Library
    • Love’s Cup

    Oklahoma City Office

    840 Research Parkway, Suite 250
    OKC, OK 73104
    PHONE 405/235-2305
    Click HERE for printable map with directions.

    Tulsa Office

    618 E. Third Street, Suite 1
    Tulsa, OK 74120
    PHONE 918/582-5592
    Click HERE for printable map with directions.
    Copyright 2021 i2E, Inc. | All Rights Reserved
    • #withOklahomaStartups
    • #withOklahomaStartups
    • #withOklahomaStartups- copy
    • 2016 BrewFest
    • 2018 Paulsen Award Application
    • 2019 Business Plan Submittal Form
    • 2019 Intent to Compete
    • 2019 Oral Competition Submittal Form
    • 2019 Paulsen Award Application
    • 2020 Business Plan Submittal Form
    • 2020 Oral Competition Submittal Form
    • 2020 Paulsen Award Application
    • 2021 Official Application Form
    • 2021 Oral Competition Submittal Form
    • 2021 Paulsen Award Application
    • 4DSales
    • About
    • About i2E
    • About Us
    • ACT Tulsa
    • Add Listing
    • Alkami
    • Biolytx
    • BP Endo
    • Clear River Enviro
    • Concept Fund
    • Contact
    • COVID-19 News from i2E
    • COVID19 Resources for Scalable Startups
    • CreditPoint
    • Datebox
    • DermaMedics
    • DEX Pump
    • DigitalSix
    • Directory
    • Directory Dashboard
    • Docvia
    • Driven Analytics
    • e3
    • e3 Goes Virtual
    • e3: #withOklahomaStartups
    • Entrepreneurial Development
    • Entrepreneurial Summit
    • Entrepreneurial Summit Speakers
    • Entrepreneurs-in-Residence
    • Entrepreneurship
    • Events
    • Events
    • Exaptive
    • Exerbotics
    • Expert TA
    • Founder’s Book Nook
    • Home
    • Home
    • i2E Directory
    • i2E Events
    • iMCI
    • iMCI Investment Funds
    • Investments
    • iRecommend
    • Kirrhos
    • Letter from iMCI’s Executive in Residence in a time of great uncertainty
    • Library
    • Lifetone
    • Linear Health Sciences
    • Love’s Cup
      • Forms
      • High Growth
      • Paulsen Awards
      • Small Business
      • Timeline
    • Love’s Cup is Unstoppable
    • Love’s Cup W-9
    • MaxQ
    • Moleculera Labs
    • Monscierge
    • MS Pen Technologies
    • My Account
    • News
    • Newsletter
    • Newsletter Archive
    • OKBio
    • OKBio Directory
    • OMRF Glioblastoma
    • Otologics Pharmaceuticals
    • Past Winners
    • PhotoniCare
    • PolySkope Labs
    • Portfolio
    • Portfolio 3
    • Private Partners Opportunity Fund
    • Progentec Diagnostics
    • Q&A with Kevin Moore
    • Q&A with Michael Basch
    • Quarterly Report
    • Raw Space for Rent
    • Resources
    • Roll to Roll Technologies
    • Selexys Pharmaceuticals
    • Send a Ride
    • Simergent
    • Spiers New Technologies
    • Synercon Technologies
    • Tailwind
    • Ten Nine Technologies
    • Testimonials
    • Tetherex Pharmaceuticals
    • The Greg Main Distinguished Scholar Award
    • THG Energy Solutions
    • Thoughts from local business leaders and startup founders on the effects of COVID on their industry
    • Thoughts Post Shut In
    • Tulsa Collab: COVID-19 Efforts & Resources for Entrepreneurs
    • Tulsa GEW
    • Valve Systems International
    • Venture Advisory Services
    • Video
    • Virtuoso
    • Webmail Test Page
    • WeGoLook
    • Well Checked Systems
    • Whiteboard CRM
    i2E